Photo credit: https://hivglasgow.org/
At this year’s HIV Glasgow Conference, Dr Anchalee Avihingsanon presented the results of the ALLIANCE Phase III study. This clinical trial is the first of its kind to randomly compare between TAF-based Biktarvy and TDF-based regimens (TDF/FTC/DTG). It was reported that Biktarvy was able to suppress HIV-1 RNA and HBV DNA in 99% and 80.2%, respectively, of the patients co-infected with HIV/HBV with good long-term efficacy and safety at week 144. At 48 weeks, there was a rapid decline of HBV DNA but at weeks 90-96, the performance of both drugs were comparable. The clinical benefits of Biktarvy outweighs the concern of weight gain, one of the side effects of DTG.
Reference
